Letter Regarding AHA Scientific Statement “Drugs That May Cause or Exacerbate Heart Failure”

To the Editor:

The AHA Scientific Statement “Drugs That May Cause or Exacerbate Heart Failure” by Page et al.\(^1\) broadly reviews medications that may impact negatively on heart failure (HF). While we applaud Page et al. for taking on this important topic, the statement overlooks key evidence relating to dipeptidyl peptidase-4 inhibitors (DPP4is). Specifically, the review omits consideration of the HF results of the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) published in June 2015,\(^2\) and the recent TECOS secondary analysis by McGuire et al.\(^3\) focusing specifically on hospitalization for HF.

Page et al. mention the “potential increase in HF hospitalization” indicated by results of the SAVOR-TIMI 53 (saxagliptin) and EXAMINE\(^4,5\) (alogliptin) trials, a claims database analysis of sitagliptin use in a cohort of 7620 patients with type 2 diabetes mellitus and incident HF, and a meta-analysis of randomized trials of DPP4is and HF. In addition, their Table 1 indicates that the “Magnitude of HF induction or precipitation” with sitagliptin is “major” and that this “may be a class effect.” However, the TECOS main results and detailed secondary analyses found no impact of sitagliptin on hospitalization for HF with no difference in incidence—3.1% (228/7332) vs. 3.1% (n = 229/7339) for sitagliptin and placebo, respectively—or in rates—1.07 vs. 1.09 per 100 patient-years, respectively (hazard ratio 1.00; 95% CI 0.83–1.20; P=0.98).\(^2\) McGuire et al. also found no increased risk of hospitalization for HF with sitagliptin among patients with a history of HF, and no increased risk of fatal HF events.\(^3\)

Although TECOS showed no effect of sitagliptin on hospitalization for HF, concerns may remain with respect to saxagliptin given the 27% (P=0.007) increased risk of hospitalization for HF in SAVOR-TIMI 53, and alogliptin with a non-significant 19% excess seen in EXAMINE.\(^4\) These saxagliptin and alogliptin results led to an FDA Drug Safety Communication on April 5, 2016, concerning the potential heart failure risk specifically with these two agents (http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm). The meta-analysis of the hospitalization for HF results from SAVOR-TIMI 53, EXAMINE, and TECOS conducted by McGuire et al. is reassuring in that it showed no significant increased risk of HF when the three studies were combined (class hazard ratio 1.14; 95% CI 0.97–1.34; P=0.16, I\(^2\) = 44.9),\(^3\) albeit with moderate heterogeneity.

We respectfully suggest that the section of the statement regarding DPP4is be amended at the earliest opportunity.

Sincerely,

Eric D. Peterson, MD, MPH
Duke Clinical Research Institute,
Duke University School of Medicine, Durham, NC
TECOS Co-Principal Investigator and
Joint Chair of TECOS Executive Committee

Paul W. Armstrong, MD
Canadian VIGOUR Centre
University of Alberta
Edmonton, Alberta, Canada
TECOS Executive Committee Member

Rury R. Holman, MB, ChB
Diabetes Trials Unit, OCDEM
Churchill Hospital, Oxford, United Kingdom
TECOS Co-Principal Investigator and
Joint Chair of TECOS Executive Committee

References


Response:

We very much appreciate the comments by Peterson et al and bringing attention to the findings from the secondary analysis of the Trial Evaluating Cardiovascular Outcomes With Sitagliptin TECOS by McGuire et al which focused specifically on hospitalization for heart failure (HF). As Peterson et al have highlighted, the secondary findings of TECOS demonstrated a neutral effect on the endpoint of hospitalization for HF risk in patients with type 2 diabetes mellitus at high cardiovascular risk (adjusted HF, 1.02; 95% CI, 0.83-1.26). However, it is important to highlight that of those with a history of a first hospitalization for HF (n=457), the majority were New York Heart Association (NYHA) functional class I-II (58.1%) in which 1.6% had NYHA class IV and 23.6% did not have a NYHA reported. Thus, the effect on the risk of HF hospitalization in patients with more severe heart failure will need to be explored.

The data surrounding the use of dipeptidyl peptidase-4 (DPP-4) inhibitor class and their effects on HF hospitalizations in patients with and without HF continues to evolve and unfortunately the findings from the secondary analysis of TECOS were published while our statement was in production. Nonetheless, we agree with Peterson et al that the secondary findings from TECOS does bring reassurance that sitagliptin appears to have a better cardiovascular safety profile within this class. In regards to a “class effect” of these drugs, we will eagerly await the findings from the Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes (CAROLINA) trial. This study is a large, international, randomized trial in subjects with early type 2 diabetes and increased cardiovascular risk or established complications that will determine the long-term cardiovascular safety of linagliptin versus the sulfonylurea. Of note, CAROLINA will also address, through independent adjudication, whether hospitalizations for HF are increased with linagliptin or glimepiride and HF related mortality occurs more frequently. Until the publication of CAROLINA, we recommend caution and close monitoring with the use of DPP-4 inhibitors, particularly with saxagliptin and alogliptin, when used in patients with HF.

Robert L Page II, PharmD, MSPH
Professor
University of Colorado Skaggs School of Pharmacy

JoAnn Lindenfeld, MD
Professor and Medical Director Heart Failure and Transplantation Programs
Vanderbilt School of Medicine

References:
